oxybutynin FDA Alerts
The FDA Alert(s) below may be specifically about oxybutynin or relate to a group or class of drugs which include oxybutynin.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.
Recent FDA Alert(s) for oxybutynin
Warfarin Sodium Tablets (Jantoven), 3mg: Recall - Mislabeled Bottles Containing Higher Dosage
Feb 21, 2011
Audience: Pharmacy, Family Practice, Consumer
[UPDATED 02/21/2011] Expansion of Recall: Affected Products Include Amantadine, Amlodipine, Androxy, Baclofen, Bethanechol, Jantoven and Oxybutynin
ISSUE: Upsher-Smith Laboratories and FDA notified healthcare professionals of the recall of one lot of Jantoven Warfarin Sodium, USP, 3mg Tablets, an anticoagulant, after a single bottle labeled as Jantoven Warfarin Sodium, USP, 3mg Tablets was found to contain tablets at a higher 10mg strength. To date, the company has identified no additional mislabeled bottles.
BACKGROUND: The recalled lot is numbered as #284081, with an expiration date of September 2012. The product lot was distributed to wholesalers, retail chains and independent pharmacies throughout the United States. The primary risk of substituting 10mg warfarin for 3mg warfarin is overdosing more than 3 times the labeled amount which leads to excessive anticoagulation that could be expected to result in life-threatening hemorrhage in patients.
RECOMMENDATION: The two Jantoven tablets (see photo at link below) can be readily identified by color: the 3mg tablet is tan and the 10mg tablet is white. In addition, the 3mg tablet is imprinted with the letters WRF, a line, and the number 3 below the line. The reverse side of the 3mg tablet carries the number 832. The 10mg tablet is imprinted with the letters WRF, a line, and the number 10 below the line. The reverse side of the 10mg tablet carries the number 832. Consumers and pharmacists can call the Upsher-Smith medical information line at 1-888-650-3789 for more information and to access product details, Monday-Friday between 8:00 a.m. and 5:00 p.m. (CST).
Healthcare professionals and patients are encouraged to report adverse events, side effects, or product quality problems related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
More oxybutynin Resources
- Oxybutynin Consumer Information
- Oxybutynin transdermal Consumer Information
- Oxybutynin Extended-Release Tablets Consumer Information
- Oxybutynin Tablets Consumer Information
- Oxybutynin Gel Consumer Information
- Oxybutynin Syrup Consumer Information
- Oxybutynin Transdermal System Consumer Information
- Oxybutynin Advanced Consumer Information
- Oxybutynin Transdermal Advanced Consumer Information
- Oxybutynin Chloride AHFS DI Monograph
- Oxybutynin Prescribing Information
- Oxybutynin ER Tablets Prescribing Information
- Oxybutynin Oral Solution Prescribing Information
- Oxybutynin Syrup Prescribing Information
- Oxybutynin A-Z Drug Facts